Novel Approaches for Preventing or Limiting Events (Naples) II TrialImpact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction
Carlo Briguori, MD, PhD*, ,*,
Gabriella Visconti, MD*,
Amelia Focaccio, MD*,
Bruno Golia, MD*,
Alaide Chieffo, MD,
Alfredo Castelli, MD,
Marco Mussardo, MD,
Matteo Montorfano, MD,
Bruno Ricciardelli, MD* and
Antonio Colombo, MD
* Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy
Laboratory of Interventional Cardiology, "Vita e Salute" University School of Medicine, San Raffaele Scientific Institute, Milan, Italy
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flow Chart of the Study
Diagram showing the flow of participants through each stage of the trial. CABG = coronary artery bypass grafting; ISR = in-stent restenosis; PCI = percutaneous coronary intervention.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 CK-MB Increase in the 2 Treatment Groups
(A) Incidence of creatine kinase-myocardial isoenzyme (CK-MB) increase >3x the upper limit of normal (ULN) in the atorvastatin group and in the control group. (B) Incidence of CK-MB increase >3x ULN in the subgroup of patients with normal and high C-reactive protein (CRP) in both the atorvastatin group and in the control group. CI = confidence interval; OR = odds ratio.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Troponin I Increase in the 2 Treatment Groups
(A) Incidence of troponin I (TnI) increase >3x ULN in the atorvastatin group and in the control group. (B) Incidence of TnI increase >3x ULN in the subgroup of patients with normal and high CRP in both the atorvastatin group and in the control group. Abbreviations as in Figure 2.
|
|
|
